Venrock Adviser, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001615982
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 36 positions · Total reported value $1.46B · Top-10 concentration 68.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 35.1% · 4 new · 5 cut · 4 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +24.9% · vs SPY +10.0% · Prev Value $2.68B — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2023 13F filing, Venrock Adviser, LLC disclosed 36 equity positions with a combined reported value of $1.46B. The filing implies a focused portfolio: its ten largest positions account for 68.3% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were RYZB ($250.57M), APGE ($237.30M), PHVS ($95.25M). By sector, the heaviest allocations are Health Care 45.7%, Industrials 0.4%. Versus the prior quarter, allocation shifted toward Other (+5.4pp) and away from Health Care (-5.8pp).
Versus the prior quarter, Venrock Adviser, LLC opened 4 new positions, trimmed 5 and fully exited 4, a turnover rate of 35.1% of positions. The portfolio's overlap with the prior quarter was 70% of names.
The largest new positions opened in Q4 2023 were SYRE ($51.06M), OCUL ($34.68M), ARVN ($25.84M).
Of the 4 positions fully exited versus the prior quarter, the largest were TVTX ($23.46M), ACRS ($7.13M), PLRX ($5.01M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
Fully Exited (vs previous quarter)
- TVTX TRAVERE THERAPEUTICS INC · prev qtr: $23.46M
- ACRS ACLARIS THERAPEUTICS INC · prev qtr: $7.13M
- PLRX PLIANT THERAPEUTICS INC · prev qtr: $5.01M
- SGMT SAGIMET BIOSCIENCES INC-A COMP · prev qtr: $4.53M
- AGLE CASTLE BIOSCIENCES INC · prev qtr: $3.61M
- RLYB RALLYBIO CORP · prev qtr: $904.95K
- AFMD AFFIMED N V · prev qtr: $682.71K
Insider Transactions (Form 4)
Latest Venrock Adviser, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Venrock Adviser, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 33 US equity positions with a combined value of $3.30B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-79382 (status: Approved), registered 2014-04-09
- Regulatory AUM (Form ADV): $4.50B as of 2026-04-28
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 7 private funds, of which 1 hedge funds
Portfolio Structure
- 33 positions · $3.30B reported value (Q2 2026)
- Top 10 holdings = 80.4% of reported value
- Largest position: APGE (APOGEE THERAPEUTICS INC) at 34.2%
- Average position size: $99.94M
Sector Tilt
- Health Care 65.7%
- Financials 0.1%
- (classified holdings cover 66% of value)
Quarterly Activity
- Q2 2026: 4 new, 5 added, 5 reduced, 4 exited
- 19 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
4.03M | $250.57M | 17.18% | Hold | |
| 2 |
|
8.49M | $237.30M | 16.27% | Hold | |
| 3 |
|
3.40M | $95.25M | 6.53% | Add | |
| 4 |
|
3.88M | $84.56M | 5.80% | Add | |
| 5 |
|
3.42M | $69.37M | 4.76% | Add | |
| 6 |
|
2.15M | $59.08M | 4.05% | Add | |
| 7 |
|
2.56M | $58.20M | 3.99% | Add | |
| 8 |
|
2.37M | $51.06M | 3.50% | New | |
| 9 |
|
4.09M | $50.14M | 3.44% | Add | |
| 10 |
|
2.95M | $40.90M | 2.81% | Hold | |
| 11 |
|
7.78M | $34.68M | 2.38% | New | |
| 12 |
|
2.08M | $33.30M | 2.28% | Add | |
| 13 |
|
2.07M | $29.48M | 2.02% | Hold | |
| 14 |
|
4.50M | $29.19M | 2.00% | Add | |
| 15 |
|
2.17M | $28.91M | 1.98% | Hold | |
| 16 |
|
4.68M | $27.54M | 1.89% | Hold | |
| 17 |
|
1.89M | $27.47M | 1.88% | Reduce | |
| 18 |
|
11.33M | $26.28M | 1.80% | Hold | |
| 19 |
|
627.79K | $25.84M | 1.77% | New | |
| 20 |
|
3.23M | $24.77M | 1.70% | New | |
| 21 |
|
495.98K | $22.80M | 1.56% | Reduce | |
| 22 |
|
2.43M | $22.34M | 1.53% | Add | |
| 23 |
|
6.25M | $20.94M | 1.44% | Add | |
| 24 |
|
10.41M | $18.43M | 1.26% | Reduce | |
| 25 |
|
3.50M | $16.45M | 1.13% | Reduce | |
| 26 |
|
2.58M | $13.50M | 0.93% | Add | |
| 27 |
|
998.57K | $10.68M | 0.73% | New | |
| 28 |
|
927.71K | $9.65M | 0.66% | Hold | |
| 29 |
|
353.63K | $7.88M | 0.54% | Reduce | |
| 30 |
|
1.32M | $7.65M | 0.52% | Reduce | |
| 31 |
|
937.11K | $6.99M | 0.48% | Add | |
| 32 |
|
250.00K | $5.78M | 0.40% | New | |
| 33 |
|
3.42M | $4.59M | 0.32% | Hold | |
| 34 |
|
5.15M | $3.88M | 0.27% | Reduce | |
| 35 |
|
925.05K | $1.54M | 0.11% | Reduce | |
| 36 |
|
77.04K | $1.08M | 0.07% | Hold | |
FAQ
What did Venrock Adviser, LLC buy in 2023-Q4?
In its 2023-Q4 13F filing, Venrock Adviser, LLC reported 36 equity positions worth $1.46B in aggregate; its largest disclosed positions were RYZB ($250.57M), APGE ($237.30M), PHVS ($95.25M).
How large is Venrock Adviser, LLC's portfolio?
Venrock Adviser, LLC reported $1.46B of long equity holdings across 36 positions as of 2023-Q4. Top-10 holdings account for 68.3% of reported value.
What is Venrock Adviser, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.